Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Sets New 12-Month High – Should You Buy?

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) shares hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $36.5850 and last traded at $36.5850, with a volume of 167 shares. The stock had previously closed at $35.25.

Analyst Ratings Changes

Separately, Deutsche Bank Aktiengesellschaft raised shares of Swedish Orphan Biovitrum from a “sell” rating to a “buy” rating in a research note on Monday, November 3rd. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Buy rating to the stock. According to data from MarketBeat.com, Swedish Orphan Biovitrum presently has an average rating of “Strong Buy”.

Swedish Orphan Biovitrum Stock Up 3.8%

The firm has a market capitalization of $13.02 billion, a price-to-earnings ratio of -522.64 and a beta of 0.37. The company has a debt-to-equity ratio of 0.24, a quick ratio of 0.69 and a current ratio of 1.02. The business has a 50 day simple moving average of $34.94 and a 200-day simple moving average of $31.91.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last issued its quarterly earnings results on Monday, October 20th. The company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.49 by $0.15. The company had revenue of $826.53 million during the quarter, compared to analysts’ expectations of $818.86 million. Swedish Orphan Biovitrum had a negative net margin of 0.97% and a positive return on equity of 13.66%.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm?based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high?value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in?licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto?inflammatory conditions.